ClinicalTrials.gg
CompletedNCT02084082Updated Aug 4, 2016Results posted

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (5mg/1000mg) Extended Release in Healthy Subjects

A Phase 1 interventional study of Linagliptin/Metformin ER FDC and Linagliptin in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-08-04.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this trial is to demonstrate bioequivalence of a newly developed fixed dose combination (FDC) tablet containing linagliptin and metformin extended release compared to the free combination of linagliptin and metformin extended release, both under fed and fasted conditions.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female subjects

Exclusion criteria

Exclusion criteria:

  • Any relevant deviation from healthy condition
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    FDC first, fasted

    Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fasted condition

    Drug: Linagliptin/Metformin ER FDC · Drug: Linagliptin · Drug: Metformin ER

  • Experimental
    Single tablets first, fasted

    single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fasted condition

    Drug: Linagliptin/Metformin ER FDC · Drug: Linagliptin · Drug: Metformin ER

  • Experimental
    FDC first, fed

    Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fed condition

    Drug: Linagliptin/Metformin ER FDC · Drug: Linagliptin · Drug: Metformin ER

  • Experimental
    Single tablets first, fed

    single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fed condition

    Drug: Linagliptin/Metformin ER FDC · Drug: Linagliptin · Drug: Metformin ER

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72)

    AUC 0-72 (area under concentration-time curve of the Linagliptin in plasma from 0 to 72 hours) The values for geometric mean and geometric coefficient of variation (gCV) are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h,1h 30min, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h,34h, 48h and 72h after drug administration

  2. Maximum Measured Concentration of Linagliptin in Plasma (Cmax)

    Cmax (maximum measured concentration of Linagliptin in plasma) The values for geometric mean and geometric coefficient of variation (gCV) are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h,1h 30min, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h,34h, 48h and 72h after drug administration

  3. Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    AUC 0-t (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) The values for geometric mean and geometric coefficient of variation (gCV) are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h,1h 30min, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h,34h, 48h and 72h after drug administration

  4. Cmax of Metformin in Plasma

    Cmax (maximum measured concentration of the Metformin in plasma) The values for geometric mean and geometric coefficient of variation (gCV) are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h,1h 30min, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h,34h, 48h and 72h after drug administration

Secondary outcomes

  1. Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf)

    AUC0-inf (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) for Linagliptin. The values for geometric mean and geometric coefficient of variation (gCV) are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h,1h 30min, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h,34h, 48h and 72h after drug administration

  2. AUC0-inf of Metformin in Plasma

    AUC0-inf(area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) for Metformin. The values for geometric mean and geometric coefficient of variation (gCV) are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h,1h 30min, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h,34h, 48h and 72h after drug administration

07

Results

Posted Aug 4, 2016

Participant flow

The study is conducted in two parts: Part 1 of the study was conducted in fasting conditions. Part 2 of the study was conducted in fed conditions.

Treatment Period 1 (4 Days)
Participant flow — Treatment Period 1 (4 Days)
MilestoneFDC 1000 Fast/ L+M 1000 FastL+M1000 Fast/ FDC1000 FastFDC1000 Fed/L+M1000 FedL+M1000 Fed/ FDC1000 Fed
Started262688
Completed262688
Not completed0000
Washout Period 1 (35 Days)
Participant flow — Washout Period 1 (35 Days)
MilestoneFDC 1000 Fast/ L+M 1000 FastL+M1000 Fast/ FDC1000 FastFDC1000 Fed/L+M1000 FedL+M1000 Fed/ FDC1000 Fed
Started262688
Completed262676
Not completed0012
Withdrew: Adverse event0011
Withdrew: Withdrawal by subject0001
Treatment Period 2 (4 Days)
Participant flow — Treatment Period 2 (4 Days)
MilestoneFDC 1000 Fast/ L+M 1000 FastL+M1000 Fast/ FDC1000 FastFDC1000 Fed/L+M1000 FedL+M1000 Fed/ FDC1000 Fed
Started262676
Completed262676
Not completed0000

Outcome measures

PrimaryArea Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72)

AUC 0-72 (area under concentration-time curve of the Linagliptin in plasma from 0 to 72 hours) The values for geometric mean and geometric coefficient of variation (gCV) are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h,1h 30min, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h,34h, 48h and 72h after drug administration
Reported as:
Geometric mean · nmol*h/L
Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72)
nmol*h/LL+M 1000 FastedFDC 1000 FastedL+M 1000 FedFDC 1000 Fed
Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72)286.639 ± 11.8287.696 ± 11.8234.052 ± 9.2221.644 ± 9.2
Statistical analysis
  • L+M 1000 Fasted vs FDC 1000 Fasted · ANOVA · p = <0.0001 · Adjusted geometric means ratio: 100.37 · 90% CI 96.562 to 104.326Ratio of (FDC 1000_fasted/ L+M 1000 fasted)
  • L+M 1000 Fed vs FDC 1000 Fed · ANOVA · p = 0.0004 · Geometric mean ratio (net): 94.70 · 90% CI 88.712 to 101.089Ratio of (FDC 1000 Fed/ L+M 1000 Fed)
PrimaryMaximum Measured Concentration of Linagliptin in Plasma (Cmax)

Cmax (maximum measured concentration of Linagliptin in plasma) The values for geometric mean and geometric coefficient of variation (gCV) are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h,1h 30min, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h,34h, 48h and 72h after drug administration
Reported as:
Geometric mean · nmol/L
Maximum Measured Concentration of Linagliptin in Plasma (Cmax)
nmol/LL+M 1000 FastedFDC 1000 FastedL+M 1000 FedFDC 1000 Fed
Maximum Measured Concentration of Linagliptin in Plasma (Cmax)8.826 ± 27.19.540 ± 27.15.791 ± 6.15.689 ± 6.1
Statistical analysis
  • L+M 1000 Fasted vs FDC 1000 Fasted · ANOVA · p = 0.0038 · Adjusted geometric mean ratio: 108.09 · 90% CI 99.022 to 117.989Ratio of (FDC 1000_fasted/ L+M 1000 fasted)
  • L+M 1000 Fed vs FDC 1000 Fed · ANOVA · p = <0.0001 · Adjusted geometric means ratio: 98.24 · 90% CI 94.067 to 102.597Ratio of (FDC 1000_fed / L+M 1000 fed)
PrimaryArea Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

AUC 0-t (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) The values for geometric mean and geometric coefficient of variation (gCV) are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h,1h 30min, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h,34h, 48h and 72h after drug administration
Reported as:
Geometric mean · ng∙h/mL
Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
ng∙h/mLL+M 1000 FastedFDC 1000 FastedL+M 1000 FedFDC 1000 Fed
Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)7146.61 ± 22.27146.00 ± 22.211326.12 ± 7.110980.17 ± 7.1
Statistical analysis
  • L+M 1000 Fasted vs FDC 1000 Fasted · ANOVA · p = <0.0001 · Adjusted geometric mean ratio: 99.99 · 90% CI 93.03 to 107.47Ratio of (FDC 1000_fasted/ L+M 1000 fasted)
  • L+M 1000 Fed vs FDC 1000 Fed · ANOVA · p = <0.0001 · Adjusted geometric means ratio: 96.95 · 90% CI 92.24 to 101.89Ratio of (FDC 1000_fed / L+M 1000 fed)
PrimaryCmax of Metformin in Plasma

Cmax (maximum measured concentration of the Metformin in plasma) The values for geometric mean and geometric coefficient of variation (gCV) are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h,1h 30min, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h,34h, 48h and 72h after drug administration
Reported as:
Geometric mean · ng/mL
Cmax of Metformin in Plasma
ng/mLL+M 1000 FastedFDC 1000 FastedL+M 1000 FedFDC 1000 Fed
Cmax of Metformin in Plasma925.709 ± 23.4923.543 ± 23.4947.445 ± 5.9937.685 ± 5.9
Statistical analysis
  • L+M 1000 Fasted vs FDC 1000 Fasted · ANOVA · p = <0.0001 · Adjusted geometric means ratio: 99.77 · 90% CI 92.464 to 107.645Ratio of (FDC 1000_fasted/ L+M 1000 fasted)
  • L+M 1000 Fed vs FDC 1000 Fed · ANOVA · p = <0.0001 · Adjusted geometric means ratio: 98.97 · 90% CI 94.950 to 103.160Ratio of (FDC 1000_fed / L+M 1000 fed)
SecondaryArea Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf)

AUC0-inf (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) for Linagliptin. The values for geometric mean and geometric coefficient of variation (gCV) are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h,1h 30min, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h,34h, 48h and 72h after drug administration
Reported as:
Geometric mean · nmol*h/L
Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf)
nmol*h/LL+M 1000 FastedFDC 1000 FastedL+M 1000 FedFDC 1000 Fed
Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf)461.306 ± 14.3460.009 ± 14.3397.945 ± 32.4387.424 ± 32.4
Statistical analysis
  • L+M 1000 Fasted vs FDC 1000 Fasted · ANOVA · p = <0.0001 · Adjusted geometric means ratio: 99.72 · 90% CI 95.163 to 104.493Ratio of (FDC 1000_fasted/ L+M 1000 fasted)
  • L+M 1000 Fed vs FDC 1000 Fed · ANOVA · p = 0.0778 · Adjusted geometric means ratio: 97.36 · 90% CI 77.082 to 122.963Ratio of (FDC 1000_fed / L+M 1000 fed)
SecondaryAUC0-inf of Metformin in Plasma

AUC0-inf(area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) for Metformin. The values for geometric mean and geometric coefficient of variation (gCV) are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h,1h 30min, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h,34h, 48h and 72h after drug administration
Reported as:
Geometric mean · ng∙h/mL
AUC0-inf of Metformin in Plasma
ng∙h/mLL+M 1000 FastedFDC 1000 FastedL+M 1000 FedFDC 1000 Fed
AUC0-inf of Metformin in Plasma7607.75 ± 21.77540.21 ± 21.715047.37 ± 7.214773.59 ± 7.2
Statistical analysis
  • L+M 1000 Fasted vs FDC 1000 Fasted · ANOVA · p = <0.0001 · Adjusted geometric means ratio: 99.11 · 90% CI 92.37 to 106.35Ratio of (FDC 1000_fasted/ L+M 1000 fasted)
  • L+M 1000 Fed vs FDC 1000 Fed · ANOVA · p = <0.0001 · Adjusted geometric means ratio: 98.18 · 90% CI 93.34 to 103.27Ratio of (FDC 1000_fed / L+M 1000 fed)

Adverse events

Collected over From the first drug administration for at least 7 days after the last drug administration, up to 49 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
L+M 1000 Fasted—0/52 (0%)4/52 (7.7%)
FDC 1000 Fasted—0/52 (0%)9/52 (17.3%)
L+M 1000 Fed—2/15 (13.3%)4/15 (26.7%)
FDC 1000 Fed—0/14 (0%)4/14 (28.6%)
Most frequent serious events
Most frequent serious events
EventL+M 1000 FastedFDC 1000 FastedL+M 1000 FedFDC 1000 Fed
Acetabulum fractureInjury, poisoning and procedural complications0/520/521/150/14
Bone contusionInjury, poisoning and procedural complications0/520/521/150/14
ConcussionInjury, poisoning and procedural complications0/520/521/150/14
FallInjury, poisoning and procedural complications0/520/521/150/14
Muscle contusionInjury, poisoning and procedural complications0/520/521/150/14
Pelvic fractureInjury, poisoning and procedural complications0/520/521/150/14
Road traffic accidentInjury, poisoning and procedural complications0/520/521/150/14
Most frequent other events
Most frequent other events
EventL+M 1000 FastedFDC 1000 FastedL+M 1000 FedFDC 1000 Fed
HeadacheNervous system disorders3/525/522/150/14
DiarrhoeaGastrointestinal disorders1/524/520/151/14
FatigueGeneral disorders0/520/520/151/14
RhinitisInfections and infestations0/522/520/151/14
Decreased appetiteMetabolism and nutrition disorders0/520/520/151/14
RashSkin and subcutaneous tissue disorders0/520/520/151/14
VertigoEar and labyrinth disorders0/520/521/150/14
Abdominal discomfortGastrointestinal disorders0/520/521/150/14
DizzinessNervous system disorders0/522/521/150/14

Baseline characteristics

Treated set: All randomised subjects who received 1 dose of trial medication were included in the treated set.

Age, Continuous
Age, Continuous(years)FDC 1000 Fast or L+M 1000 FastFDC 1000 Fed or L+M 1000 FedTotal
Mean34.7 ± 10.436.1 ± 11.935.0 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)FDC 1000 Fast or L+M 1000 FastFDC 1000 Fed or L+M 1000 FedTotal
Female291039
Male23629
08

Study locations

1 site
  • 1288.9.1 Boehringer Ingelheim Investigational Site
    Biberach, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2014
First posted
Mar 11, 2014
Start
Apr 2014
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Results first posted
Aug 4, 2016
Last update
Aug 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02084082
Responsible party
Sponsor
First posted
Mar 11, 2014
Start date
Apr 2014
Primary completion
Jul 2014
Completion
Jul 2014
Results posted
Aug 4, 2016
Last update
Aug 4, 2016

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Linagliptin · Metformin

Start the discussion